SCHEMBL15875458

SCHEMBL15875458

O=C(O)COCCc1cnnn1Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.61
SIRT2 Q8IXJ6 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
DUT P33316 1/20 0.39
FFAR4 Q5NUL3 3/20 0.39
P2RX7 Q99572 1/20 0.39
HPGD P15428 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CYP1A2 P05177 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTGS2 P35354 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15875668 0.85 HSD11B1 (0.53) HSD11B1SIRT2SIRT1DUTP2RX7
SCHEMBL21606708 0.82 HSD11B1 (0.77) HSD11B1SIRT2SIRT1P2RX7HPGD
SCHEMBL20841014 0.78 HSD11B1 (0.56) HSD11B1SIRT2SIRT1DUTP2RX7
SCHEMBL15874678 0.77 HSD11B1 (0.65) HSD11B1SIRT2SIRT1DUTP2RX7
SCHEMBL21606733 0.75 HSD11B1 (0.67) HSD11B1SIRT2SIRT1HPGDL3MBTL1
SCHEMBL4195851 0.75 HSD11B1 (0.61) HSD11B1SIRT2SIRT1P2RX7HPGD
SCHEMBL21606911 0.74 HSD11B1 (0.65) HSD11B1SIRT2SIRT1SMN1; SMN2PTGS2
SCHEMBL3248092 0.73 FFAR4 (0.55) FFAR4HDAC3HDAC1HDAC2HDAC10
SCHEMBL23812236 0.72 HSD11B1 (0.59) HSD11B1SIRT2SIRT1DUTHDAC3
SCHEMBL21606709 0.72 HSD11B1 (0.61) HSD11B1SIRT2SIRT1GAAHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2943494-B1 PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN LILLY CO ELI (US) 2017-02-22 EP disclosed
EP-2943494-B1 PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN LILLY CO ELI (US) 2017-02-22 EP disclosed
EP-2943494-A1 PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN Eli Lilly and Company (US) 2015-11-18 EP disclosed
US-8969555-B2 Bicyclic pyrimidine compounds ELI LILLY AND COMPANY (US) 2015-03-03 US disclosed
US-8969555-B2 Bicyclic pyrimidine compounds ELI LILLY AND COMPANY (US) 2015-03-03 US disclosed
US-8969555-B2 Bicyclic pyrimidine compounds ELI LILLY AND COMPANY (US) 2015-03-03 US disclosed
US-20140200231-A1 Bicyclic Pyrimidine Compounds ELI LILLY AND COMPANY (US) 2014-07-17 US disclosed
US-20140200231-A1 Bicyclic Pyrimidine Compounds ELI LILLY AND COMPANY (US) 2014-07-17 US disclosed
WO-2014110000-A1 PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN ELI LILLY AND COMPANY (US) 2014-07-17 WO disclosed
WO-2014110000-A1 PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN ELI LILLY AND COMPANY (US) 2014-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200231-A1 Bicyclic Pyrimidine Compounds ENPP2, HAX1, NUDT1 HSD11B1 3846/4885SIRT2 2111/4885SIRT1 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.